Zacks Downgrades DaVita HealthCare Partners to Hold (DVA) - WKRB News |
|
|
DaVita HealthCare Partners (NYSE:DVA) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Market Beat.com reports.
According to Zacks, “DaVita’s earnings per share in the second quarter surpassed the Zacks Consensus Estimate. The outperformance came on the back of rise in patient service, capitated and other revenues. DaVita Healthcare’s strength lies in its enhanced service offerings and compelling inorganic growth story. The company’s incessant efforts to upgrade services, its global expansion initiatives and active acquisitions remain impressive and are supported by its strong financial position. The merger of the HealthCare segment with HealthCare Partners also bodes well for long-term growth, although Medicare Advantage (MA) rate cuts may hurt this segment in the future. High debt levels, adverse effects of healthcare reforms, and an increase in MA beneficiaries are other concerns.”
In other news, COO Michael David Staffieri sold 9,050 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $84.07, for a total value of $760,833.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Robert J. Margolis sold 31,400 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $83.39, for a total value of $2,618,446.00. The disclosure for this sale can be found here.
DaVita HealthCare Partners (NYSE:DVA) traded down 0.15% during mid-day trading on Friday, reaching $81.02. The company had a trading volume of 1,107,146 shares. DaVita HealthCare Partners has a 12-month low of $71.43 and a 12-month high of $85.17. The stock has a 50-day moving average of $79.90 and a 200 day moving average of $79.87. The company has a market capitalization of $17.42 billion and a price-to-earnings ratio of 40.96.
DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.95 earnings per share (EPS) for the quarter, hitting the Thomson Reuters consensus estimate of $0.95. The firm earned $3.43 billion during the quarter, compared to the consensus estimate of $3.37 billion. DaVita HealthCare Partners’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.95 EPS. On average, analysts expect that DaVita HealthCare Partners will post $3.76 EPS for the current year.
Other analysts also recently issued reports about the company. RBC Capital increased their price target on DaVita HealthCare Partners from $60.00 to $83.00 and gave the company a “sector perform” rating in a research report on Thursday. Vetr downgraded DaVita HealthCare Partners from a “strong-buy” rating to a “buy” rating and set a $88.97 target price for the company. in a research report on Monday, July 13th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $80.00 price target on shares of DaVita HealthCare Partners in a report on Tuesday, May 12th. Piper Jaffray lifted their price objective on DaVita HealthCare Partners from $87.00 to $88.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Susquehanna reaffirmed a “neutral” rating and set a $82.00 price target (up previously from $75.00) on shares of DaVita HealthCare Partners in a research note on Saturday, May 9th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $85.20.
DaVita HealthCare Partners Inc. consists of two divisions, Kidney Care and HealthCare Partners (NYSE:DVA). Kidney Care is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). Kidney Care division develops innovative clinical care, offers integrated treatment plans, personalized care teams and health-management services. As of December 31, 2014, we provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. HealthCare Partners division is a patient- and physician-focused integrated health care delivery and management company. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, Florida and New Mexico. As of December 2014, HealthCare Partners had approximately 837,000 members under its care.
To get a free copy of the research report on DaVita HealthCare Partners (DVA), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners and related companies with MarketBeat.com's FREE daily email newsletter.
|
Global Dialysis Equipment Market: Industry Analysis and Opportunity Assessment ... - Medgadget.com (blog) |
|
|
Dialysis machines are artificial kidneys that perform kidney functions for patients who have permanent or temporary renal failure.
Dialysis machines use to cleanse the blood and balance its constituents. By the help of this process, the patient blood is circulated through the machine where it is filtered and balance for electrolytes, pH, and fluid concentration before being returned to the patient. One common problem with kidney failure is water retention, therefore it is common for the process to remove several pints of fluid from the blood of the patient.
Chronic kidney disease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Worldwide, diabetes mellitus is the most common cause of chronic disease, but in some region other causes, such as herbal and environmental toxins are more common.
Dialysis Equipment Market: Drivers and Restraints
Presently, dialysis equipment global market is driven by the aging population, by increasing incidence of end-stage kidney disease, a rising incidence of diabetes and hypertension.
Dialysis equipment global market is drives by the aging population, technological advancement in healthcare industry, increasing incidence of kidney disease, and increase in the number of diabetic and hypertension patients globally, and due to the shortage of kidney donors for transplantation. However, factors such as low awareness about kidney disease and their modalities, reduction in Medicare reimbursement to dialysis centers act as a major barriers for this market.
Browse Full Report@ http://www.futuremarketinsights.com/reports/dialysis-equipment-market
Dialysis Equipment Market: Segmentation
Global dialysis equipment market is segmented into following types
- Hemodialysis Equipment
- Hemodialysis Machines
- Dialyzers (Artificial Kidney)
- Blood Access Device Dialysate
- Peritoneal Dialysis Equipment
- Continuous Cycling Peritoneal Dialysis (CCPD)
- Continuous Ambulatory Peritoneal Dialysis (CAPD)
- Intermittent Peritoneal Dialysis
- Continuous Renal Replacement Therapy Systems
- Dialysis Accessories
Dialysis Equipment Market: Overview
With rapid technological advancement in healthcare industry, increase in aging population, and increasing incidence of kidney disease, the global dialysis equipment market is expected to have healthy growth rate in the forecast period (2015-2025).
Dialysis Equipment Market: Region-Wise Outlook
Depending on geographic regions, the dialysis equipment global market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
Due to the high population developing regions such as Asia-Pacific (Japan, China, and India) is expected to form new revenue generating pockets for the market players.
Dialysis Equipment Market: Key Players
Some of the key participating major players in dialysis equipment global market are Fresenius Medical Care AG & Co., Gambro AB, Baxter International Inc., Nipro Inc., ALLMED Medical GmbH, Asahi Kasei Corporation and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Request Report TOC@ http://www.futuremarketinsights.com/toc/rep-gb-711
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, Australia & New Zealand)
- Japan
- Middle East and Africa (S. Africa, N. Africa)
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
Our research services cover global as well as regional emerging markets such as GCC, ASEAN, and BRICS. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. FMI’s operating model blends cross-disciplinary research experience to deploy in-depth, insightful, and actionable research.
CONTACT:
Future Market Insights
Mr. Sudip saha
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.futuremarketinsights.com
|
|
Dialysis Dash Raises $26000 for New Dialysis Chairs - VOCM |
|
|
VOCM
The first ever Health Care Foundation Dialysis Dash is in the books, and was a great success. The event, a fun run and walk for all ages, saw over 200 participants at Bowring Park in St. John's. Jackie O'Brien with the Health Care Foundation says the
|
New dialysis facility to treat growing need in Topeka - Topeka Capital Journal |
|
|
A third dialysis clinic will open in Topeka later this year to accommodate a growing need for treatment of advanced kidney disease.
DaVita, which operates dialysis centers nationwide, will open a new clinic at 3711 S.W. Wanamaker. Karen Steinlage, group administrator for the DaVita facilities in Kansas, said the first patient can start treatment soon, after a last contract is signed. Subsequent patients will start after the state inspects and certifies the facility, she said.
At capacity, 24 people will be able to get their treatment in each of three shifts, Monday through Saturday. Since most patients need dialysis three times per week, they expect to treat about 144 people each week, Steinlage said.
DaVita runs Topeka Dialysis at St. Francis Health, and Fresenius Medical Care has a dialysis clinic at 3931 S.W. Gage Center and home treatment options. The new location will be more convenient for some patients, Steinlage said, and will provide more space for the growing number of people who need dialysis. She estimated the patient population has grown by 10 percent in the past decade.
“That facility (at St. Francis) is very full,” she said. “We need to grow somewhere.”
Diabetes and hypertension that weren’t properly managed are two of the major causes of kidney failure, and both have increased in recent years as obesity rates have gone up. Keelyn Ericson, a nephrologist who works with the facility, said his practice increased from three to six kidney specialists in 10 years.
“In the entire nation, there are more dialysis units each year,” he said.
Dialysis is one of few options for people who have end-stage renal failure, meaning they lost at least 85 percent of their kidney function, according to the National Kidney Foundation. Transplants also are an option, but some people have health problems that prevent them from undergoing the surgery, and there are more people waiting for an organ than available kidneys.
The process involves removing a small amount of a person’s blood at a time through a surgically created opening in his or her arm, cleaning it using osmosis with other fluids in a series of small tubes and returning it to the body. Most patients have to sit for three or four hours, and all of their blood cycles out of their bodies about eight times, Steinlage said. The waste products are essentially the same as urine, which failing kidneys can’t remove from the body, and can be disposed of through the regular sewage system, she said.
Each person is assigned his or her own machine. DaVita also can coordinate home dialysis or peritoneal dialysis, which involves a person putting the fluid into his or her abdomen and then draining it instead of using a machine, said Erin Hinrichsen, administrator of the new facility. The St. Francis location has evening hours, and they are looking into a night shift, she said.
DaVita also offers classes on managing kidney failure and preventing kidney disease, Hinrichsen said.
“So many people come to our classes and say, ‘If I just knew to watch my blood sugar, I wouldn’t be here,’” she said.
For more information about the new facility, call (785) 234-2277. To learn more about kidney health, visit Kidney.org or KidneySmart.org.
|
|